Complex metal compounds such as copper (Cu) have not been studied as alternative anticancer drugs from cisplatin. In addition, the use of ligands from complex compounds such as ditiokarbamat which has the potential as a metal poisoning drug. The combination of Cu essential metal with ditiokarbamat ligand was synthesized, namely Cu(II) Isoleucine Dithiocarbamate which was then characterized using Infra Red (IR) and Ultraviolet-Visible (UV-Vis) spectroscopy, melting point and conductivity. The anticancer activity of complex compounds was determined by in vitro using MCF-7 breast cancer cells. The test results showed that the complex (IC50=98.17 μg/mL) had significant anticancer activity comparable to cisplatin (IC50=50 μg/mL).